ICD-10 code K59. 04 for Chronic idiopathic constipation is a medical classification as listed by WHO under the range - Diseases of the digestive system .
ABSTRACT: Opioid-induced constipation (OIC) is a common adverse effect experienced by many patients on opioid therapy for chronic pain. Inadequate treatment of OIC is a barrier to the management of chronic pain and leads to a poorer quality of life. Nonpharmacologic treatment includes dietary and lifestyle changes.
Constipation. Constipation is the most common adverse effect occurring with chronic opioid use. Prophylactic treatments are essential to minimize this complication. Opioids have various effects on the gastrointestinal tract, including decreases in motility, secretions, and blood flow, which lead to hard, dry feces.
All opioids can cause constipation, but some may have less of an effect than others. Some studies have found that fentanyl may cause less constipation than morphine. Tapentadol may also be easier on your intestines than oxycodone. Methadone may also be less constipating.
Drug-induced constipation is characterized by hard stools, difficult evacuation, and/or fewer than 3 weekly bowel movements. Many medications have been associated with precipitating constipation (see Drug Reaction Data below).
Methylnaltrexone (Relistor) It is indicated for opioid-induced constipation in patients with advanced illness who are receiving palliative care when their response to laxatives has not been sufficient.
While opioids are effective drugs for pain relief, the incidence of opioid-induced constipation (OIC) varies greatly from 15% to as high as 81%. This can lead to a significant impairment in quality of life, often resulting in discontinuation of opioid therapy.
Pain medications, called “opioids” (such as morphine, hydromorphone, oxycodone and Tylenol #3,) may cause constipation. Opioids slow down the movement of stool through your bowel (intestines). This gives your bowel more time to take the water out of your stool, making it hard, dry and difficult to pass.
Opioid-induced bowel dysfunction (OIBD) comprises gastrointestinal symptoms such as constipation, anorexia, nausea, vomiting, gastro-oesophageal reflux, delayed digestion, abdominal pain, bloating, hard stool and incomplete evacuation that significantly deteriorate patients' quality of life and compliance.
The drug methylnaltrexone (MNTX) can reverse opioid-induced constipation in patients with advanced illness such as cancer or cardiovascular disease, when given every other day for a two-week period, according to a new Phase III study funded by the drug's manufacturer, Progenics Pharmaceuticals, Inc.